Surgery Partners, Inc. (SGRY) financials: revenue, earnings and cash flow
Fiscal 2015–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Surgery Partners’s revenue went from $960M in fiscal 2015 to $3.3B in fiscal 2025, growth of about 13.2% a year.
Net income in fiscal 2025 was -$78M, a net margin of -2.4%; the best year in this period was 2016 with $9M.
Over the twelve months to September 30, 2026, revenue was $3.4B and net income -$87M.
Free cash flow was $196M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 240% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.3B | $3.1B | $2.7B | $2.5B | $2.2B | $1.9B | $1.8B | $1.8B | $1.1B | $960M |
| Gross profit | — | — | — | — | — | — | — | $424M | $410M | $324M | $291M |
| Operating income | $364M | $390M | $349M | $328M | $345M | $302M | $183M | $236M | $78M | $196M | $145M |
| Net income | -$87M | -$78M | -$168M | -$12M | -$55M | -$71M | -$116M | -$75M | -$206M | $9M | $1M |
| EPS (diluted) | $-0.67 | $-0.61 | $-1.33 | $-0.09 | $-0.59 | $-1.12 | $-3.19 | $-2.29 | $-4.96 | $0.20 | $0.04 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +6.2% | +13.5% | +8.0% | +14.1% | +19.6% | +1.6% | +3.4% | +54.7% | +19.3% | +138.0% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $278M | $274M | $300M | $294M | $159M | $87M | $247M | $130M | $145M | $125M | $84M |
| Capital spending | -$75M | -$79M | -$90M | -$89M | -$81M | -$58M | -$43M | -$74M | -$40M | -$39M | -$33M |
| Free cash flow | $203M | $196M | $210M | $205M | $78M | $30M | $204M | $56M | $105M | $86M | $51M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | $0 | $0 | $2M | $0 | $0 |
| Stock-based pay | $13M | $15M | $33M | $18M | $18M | $17M | $13M | $10M | $9M | $2M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $240M | $270M | $196M | $283M | $390M | $318M | $93M | $184M | $70M | $58M |
| Debt | — | $4.0B | $3.7B | $3.1B | $2.9B | $3.3B | $3.2B | $2.9B | $2.3B | $1.4B | $1.3B |
| Equity | — | $1.7B | $1.8B | $2.0B | $2.0B | $1.1B | $116M | $297M | $405M | $10M | -$4M |
| Total assets | — | $8.1B | $7.9B | $6.9B | $6.7B | $6.1B | $5.4B | $5.0B | $4.7B | $2.3B | $2.1B |
| Shares (diluted) | 129M | 127M | 126M | 126M | 92M | 72M | 49M | 48M | 48M | 48M | 37M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | 23.1% | 23.2% | 28.3% | 30.3% |
| Operating margin | 10.8% | 11.8% | 11.2% | 12.0% | 13.6% | 13.6% | 9.8% | 12.9% | 4.4% | 17.2% | 15.1% |
| Net margin | -2.6% | -2.4% | -5.4% | -0.4% | -2.1% | -3.2% | -6.2% | -4.1% | -11.6% | 0.8% | 0.1% |
| FCF margin | 6.0% | 5.9% | 6.7% | 7.5% | 3.1% | 1.3% | 11.0% | 3.0% | 5.9% | 7.5% | 5.3% |
| ROIC | — | 5.4% | 5.0% | 5.1% | 5.5% | 5.5% | 4.4% | 5.8% | 2.2% | 10.7% | 9.1% |
| ROE | — | -4.5% | -9.4% | -0.6% | -2.7% | -6.5% | -100.4% | -25.2% | -50.8% | 97.7% | -35.5% |
Frequently asked questions
What is Surgery Partners’s annual revenue?
$3.3B in fiscal 2025 and $3.4B over the twelve months to September 30, 2026.
How much profit does Surgery Partners make?
Net income was -$78M in fiscal 2025 (net margin -2.4%).
Is Surgery Partners’s revenue growing?
Yes: revenue rose 6.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.